Literature DB >> 15513453

Metabolic optic neuropathies.

Alfredo A Sadun1.   

Abstract

Metabolic optic neuropathies form a rubric of disease characterized by bilaterally symmetrical visual impairment with loss of central visual acuity, dyschromatopsia, centrocecal visual field defects, temporal optic disc atrophy, and specific loss of the nerve fiber layer in the papillomacular bundle. The three subcategories of metabolic optic neuropathies are heredodegenerative (such as Leber's hereditary optic neuropathy), nutritional deficiencies (such as vitamins B12 or folic acid), or toxicities (such as ethambutol or cyanide). It's interesting to note that the first of these three is a congenital cause of mitochondrial impairment, whereas the latter two are acquired injuries to mitochondria. Hence, most if not all causes of metabolic optic neuropathies are, in fact, related to mitochondrial impairment. At the present time there is no effective treatment for heredodegenerative optic neuropathy. Nutritional deficiency metabolic optic neuropathies are treated by giving supplements of the appropriate nutrient or vitamin, whereas toxic metabolic optic neuropathies are treated by removing or preventing exposure to the toxin in question.

Entities:  

Mesh:

Year:  2002        PMID: 15513453     DOI: 10.1076/soph.17.1.29.10290

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  20 in total

Review 1.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Schwann cell mitochondrial metabolism supports long-term axonal survival and peripheral nerve function.

Authors:  Andreu Viader; Judith P Golden; Robert H Baloh; Robert E Schmidt; Daniel A Hunter; Jeffrey Milbrandt
Journal:  J Neurosci       Date:  2011-07-13       Impact factor: 6.167

Review 3.  Linezolid-induced optic neuropathy: a mitochondrial disorder?

Authors:  M Javaheri; R N Khurana; T M O'hearn; M M Lai; A A Sadun
Journal:  Br J Ophthalmol       Date:  2007-01       Impact factor: 4.638

4.  Axonal degeneration in peripheral nerves in a case of Leber hereditary optic neuropathy.

Authors:  Lilit Mnatsakanyan; Fred N Ross-Cisneros; Valerio Carelli; Michelle Y Wang; Alfredo A Sadun
Journal:  J Neuroophthalmol       Date:  2011-03       Impact factor: 3.042

5.  Photoreceptors in a mouse model of Leigh syndrome are capable of normal light-evoked signaling.

Authors:  Sidney M Gospe; Amanda M Travis; Alexander V Kolesnikov; Mikael Klingeborn; Luyu Wang; Vladimir J Kefalov; Vadim Y Arshavsky
Journal:  J Biol Chem       Date:  2019-06-27       Impact factor: 5.157

Review 6.  Treatment and Outcomes in Nutritional Optic Neuropathy.

Authors:  Joanna M Jefferis; Simon J Hickman
Journal:  Curr Treat Options Neurol       Date:  2019-02-07       Impact factor: 3.598

7.  Linezolid-associated optic neuropathy in a patient with ocular sarcoidosis.

Authors:  Katsuji Kiuchi; Miki Miyashiro; Chiemi Kitagawa; Sanae Wada
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

8.  Arsenic concentration variability, health risk assessment, and source identification using multivariate analysis in selected villages of public water system, Lahore, Pakistan.

Authors:  Jawairia Sultana; Abida Farooqi; Usman Ali
Journal:  Environ Monit Assess       Date:  2013-10-03       Impact factor: 2.513

9.  Association of Dietary Nitrate Intake With Primary Open-Angle Glaucoma: A Prospective Analysis From the Nurses' Health Study and Health Professionals Follow-up Study.

Authors:  Jae H Kang; Walter C Willett; Bernard A Rosner; Emmanuel Buys; Janey L Wiggs; Louis R Pasquale
Journal:  JAMA Ophthalmol       Date:  2016-03       Impact factor: 7.389

Review 10.  Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma.

Authors:  Pete A Williams; Jeffrey M Harder; Simon W M John
Journal:  J Glaucoma       Date:  2017-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.